CLVLY
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | 0.21 | $36M | $12M |
| 2025 Q4 | 0.44 | $59M | $28M |
| 2024 Q2 | 0.28 | $36M | $13M |
| 2024 Q4 | 0.49 | $55M | $10M |
| 2023 Q2 | 0.22 | $32M | $21M |
| 2023 Q4 | 0.39 | $49M | $15M |
| 2022 Q2 | 0.23 | $29M | $21M |
| 2022 Q4 | 0.30 | $41M | $22M |